Best Practices for Type 2 Diabetes Management: Update on Guidelines and New Treatment Advances

Vivian A. Fonseca, MD, FRCP, discusses best practices for the management of type 2 diabetes based on the latest guidelines and emerging treatment approaches.
Vivian A. Fonseca, MD, FRCP
Released: August 4, 2016 Expiration: No longer available for credit

Related Content

Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 1, 2020 Expired: August 31, 2021

Neil Skolnik, MD reviews GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence

John J. Russell, MD Neil Skolnik, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Nurse Practitioners: 1.0 AANP contact hour Released: July 13, 2020 Expired: July 12, 2021

Hyperglycemia can be a deadly complication for anyone with diabetes, but there are tools that can reduce this risk including GLP-1 medications. Learn more today.

Released: July 9, 2020

CME commentary: GLP-1 receptor agonists to prevent major cardiovascular adverse events (MACE) in type 2 diabetes (T2D), cardiovascular disease (CVD)

Anne Peters, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: June 8, 2020 Expired: June 7, 2021

Acknowledgements

Jointly provided by Endocrine Society and Clinical Care Options, LLC.

For questions about content or obtaining CME credit, please contact the Endocrine Society at www.education.endocrine.org/contact.

Supported by educational grants from
Merck & Co., Inc.
Novo Nordisk

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue